Hishan Tharmaseelan

Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

BrECADD in three days: Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma.

BrECADD in three days: Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma.

Journal: British journal of haematology
Published: June 23, 2026

On closing the gap: anti-PD-1-based salvage in relapsed/refractory classical Hodgkin lymphoma. Comment on: "Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma".

On closing the gap: anti-PD-1-based salvage in relapsed/refractory classical Hodgkin lymphoma. Comment on: "Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma".

Journal: Haematologica
Published: May 08, 2026

Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma.

Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma.

Journal: Cancer
Published: March 21, 2026

Comparison and combination of prognostic scores for nodular lymphocytepredominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Comparison and combination of prognostic scores for nodular lymphocytepredominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Journal: Haematologica
Published: January 29, 2026

A Matching-Adjusted Indirect Comparison of PET-Guided BrECADD Versus PET-Guided ABVD, BEACOPP, and eBEACOPP in Advanced Hodgkin Lymphoma.

A Matching-Adjusted Indirect Comparison of PET-Guided BrECADD Versus PET-Guided ABVD, BEACOPP, and eBEACOPP in Advanced Hodgkin Lymphoma.

Journal: Advances in therapy
Published: January 28, 2026

Imaging-based characterization of tumoral heterogeneity for personalized cancer treatment.

Imaging-based characterization of tumoral heterogeneity for personalized cancer treatment.

Journal: Nuklearmedizin. Nuclear medicine
Published: November 26, 2025

Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis.

Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis.

Journal: Haematologica
Published: August 18, 2025

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 17, 2025

Early Free Light-Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA-Directed CAR-T Cells.

Early Free Light-Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA-Directed CAR-T Cells.

Journal: EJHaem
Published: July 16, 2025

Sequential BCMA CAR T-cell therapy in refractory multiple myeloma.

Sequential BCMA CAR T-cell therapy in refractory multiple myeloma.

Journal: Blood advances
Published: April 01, 2025

Correction: Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

Correction: Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

Journal: Leukemia
Published: March 30, 2025

Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

Journal: Leukemia
Published: January 06, 2025
Showing 1-12 of 34

Last Updated: 09/26/2026